MTOR and hepatocellular carcinoma: Other factors associated with HCC-specific death were donor age (HR, 1.03; p = 0.031), AFP by log scale (HR, 1.10; p = 0.003), bridging therapy (HR, 0.13; p = 0.002 for none and HR, 3.39; p = 0.006 for systemic versus locoregional), viable tumor number (HR, 1.08; p < 0.001), satellite nodule (HR, 4.96; p < 0.001), and immunosuppressants (HR, 0.29; p = 0.004 for tacrolimus/mTOR inhibitor versus tacrolimus).